We welcome your feedback and / or questions related to the
educational content provided through Mechanisms in Fungal Infections.
Release date:
December 24, 2008
Expiration date:
December 24, 2009
Click here to view Technical Requirements
Accreditation
This learning activity has been designated to a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Target Audience
This learning activity is intended for oncologists, hematologists, infectious disease specialists who treat transplant patients and other patient populations at risk for developing fungal infections.
Learning Objectives
After completing this educational activity, the learner should be better able to:
- Recognize the changing epidemiology and risk factors for invasive aspergillosis and the characteristics of Aspergillus species that cause infection
- Describe the pathogenesis of this infection
- Identify typical clinical manifestations and findings of invasive aspergillosis
- Utilize current diagnostic methods for establishing an early diagnosis and appropriate management strategies in aspergillosis
- Discuss approved prophylaxis strategies in patients at high risk for the development of invasive aspergillosis
- Review and apply approved treatment options and the role of antifungal prophylaxis in high-risk patient populations
- Explain the potential development of the Immune Reconstitution Inflammatory Syndrome (IRIS) in patients with pulmonary aspergillus recovering from neutropenia.
Authors
Thomas F. Patterson, MD, FACP
Professor of Medicine
Chief, Division of Infectious Diseases
Director, San Antonio Center for Medical Mycology
University of Texas Health Science Center at San Antonio
San Antonio, Texas
George R. Thompson III, MD
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Medical Writer
Laurel McKee Ranger
Randolph, NJ
Disclosure of Financial Interests
As an accredited provider of continuing medical education, Imedex, LLC is required to ask authors to disclose any real or apparent conflict of interest they may have as related to the content of their chapter(s). The existence of commercial or financial interests of speakers related to the subject matter of their chapter(s) should not be construed as implying bias or decreasing the value of their chapter(s). However, the disclosure should help participants form their own judgments.
All authors were independently selected by the organizing committee. Those authors who disclosed affiliations or financial interests with the commercial organizations involved with products, to which the may refer are listed below.
1 = grant research
2 = consultant
3 = speaker’s bureau
4 = stock shareholder
5 = other support
Dr Thomas F. Patterson
Supporters of this activity:
Astellas Pharma US, Inc.1
Pfizer Inc1,2,3
Other affiliations:
Basilea Pharmaceutica Ltd.1,2,3
MERCK & CO., Inc.2,3
Schering-Plough1
Dr George R. Thompson III
Dr Thompson reports no affiliations with the supporters of this activity.
Other affiliations:
Basilea Pharmaceutica Ltd.1
Medical Writer
Laurel McKee Ranger
Does not report any affiliations with commercial organizations.
Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:
Keith Steward, MD, MBA, owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.
Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.
Bradley Bongiovanni, ND, Becky Lynch, RN, Emily Geiger, and Don Harting, MA, ELS own stock options for AmerisourceBergen.
Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.
Disclosure of Unapproved Uses and Investigational Drugs
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
Statement of Commercial Support
The following companies have provided unrestricted educational grants in support of this activity: Astellas Pharma US, Inc. and Pfizer Inc.
(*Please check this box to proceed - required)
|